HopeStage
Back to all studies
TerminatedNCT01834638

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.

Medication studyAges 20–66Multiple countries
The study in practice

Understand this study

What is this study about?

Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 20 years to 66 years. Other eligibility criteria apply.

Listed locations
Chino and 50 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMarch 2013
Recruitment status
Terminated
Enrollment listed in the registry
268
Sponsor
AbbVie
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, United Kingdom, Russia
Age range
From 20 Years to 66 Years
Official registry ID
NCT01834638
Official title
Show the full official title

Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855

Recruitment & locations

Terminated

Chino, United States · Costa Mesa, United States · Escondido, United States

38 more locations
  • Garden Grove, United States
  • National City, United States
  • Norwalk, United States
  • Oakland, United States
  • Oceanside, United States
  • Orange, United States
  • Pico Rivera, United States
  • Riverside, United States
  • San Bernardino, United States
  • San Diego, United States
  • San Gabriel, United States
  • Santa Ana, United States
  • Torrance, United States
  • New Haven, United States
  • Atlanta, United States
  • Marietta, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Cedarhurst, United States
  • Rochester, United States
  • Philadelphia, United States
  • DeSoto, United States
  • Houston, United States
  • Chita, Russia
  • Kazan', Russia
  • Lipetsk, Russia
  • Moscow, Russia
  • Novosibirsk, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Stavropol, Russia
  • Yaroslavl, Russia
  • Yekaterinburg, Russia
  • Edinburgh, United Kingdom
  • London, United Kingdom
  • Newcastle upon Tyne, United Kingdom
  • Oxford, United Kingdom
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.

Who is behind this study?

The study sponsor is AbbVie.

Does this study involve medication?

Yes. The study involves medication, including ABT-126.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 20 years to 66 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies